Wednesday, August 26, 2015
Biocept, a San Diego-based molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, has announced the voluntary resignation of Bill Kachioff, senior vice president and chief financial officer, to pursue other business opportunities. The company also announced that Mark G. Foletta has been appointed as the company’s interim chief financial officer, effective immediately.
With interest in personalized medicines growing, drug and diagnostics companies are investing in the development of companion diagnostics that can show that their use in conjunction with personalized therapeutics will lead to positive health outcomes, according to R&D leaders participating in a roundtable recently hosted by the Tufts Center for the Study of Drug Development (CSDD).
The FDA has granted approval of Sprout Pharmaceuticals’ Addyi (flibanserin 100mg), a once-daily, non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Addyi is the first and only FDA-approved treatment for this condition, the most common form of female sexual dysfunction, affecting up to one in 10 women in the U.S.
Remedy Pharmaceuticals, a company focused on the development and commercialization of CIRARA, a breakthrough drug for treating acute central nervous system conditions, has initiated a prospective, multicenter, open-label pilot study of CIRARA in patients with acute traumatic cervical spinal cord injuries.
23andMe, a personal genetics company, has appointed Dean Schorno, CPA, as chief financial officer and head of operations. He will oversee 23andMe’s global financial and clinical laboratory operations. Schorno brings a wealth of experience to the job, most recently working as chief financial officer of Adaptive Biotechnologies.